Prostate cancer (PCa) is the second leading cause of cancer‐related death among men in the United States, behind only lung cancer.1 It is a disease of extensive metastases with secondary lesions commonly occurring in lymph nodes, brain, bones, and sometimes in visceral organs such as the liver and lungs.2, 3 While androgen‐deprivation therapy targeted toward androgen receptor (AR) signaling is widely used for advanced PCa, this therapeutic strategy has been marred by major clinical limitations. This evidence concerns the gene AR and lung carcinoma.